Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Feb 14;9(1):2090.
doi: 10.1038/s41598-019-38853-8.

The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses

Welathanthrige S P Botheju  1 , Fawzi Zghyer  1 , Sarwat Mahmud  2 , Assel Terlikbayeva  3 , Nabila El-Bassel  4 , Laith J Abu-Raddad  5   6   7
Affiliations
Meta-Analysis

The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses

Welathanthrige S P Botheju et al. Sci Rep. .

Abstract

The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Central Asia (CA), specifically Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. A systematic review was conducted guided by the Cochrane Collaboration Handbook, and reported using PRISMA guidelines. Meta-analyses were performed using DerSimonian-Laird random-effects models with inverse variance weighting. Random-effects meta-regression analyses were performed on general population studies. The systematic review identified a total of 208 HCV prevalence measures. No incidence or Turkmenistan studies were identified. Meta-analyses estimated HCV prevalence among the general population at 0.7% (95%CI: 0.7-0.8%) in Kazakhstan, 2.0% (95%CI: 1.7-2.4%) in Kyrgyzstan, 2.6% (95%CI: 1.7-3.6%) in Tajikistan, and 9.6 (95%CI: 5.8-14.2%) in Uzbekistan. Across CA, the pooled mean prevalence was 13.5% (95%CI: 10.9-16.4%) among non-specific clinical populations, 31.6% (95%CI: 25.8-37.7%) among populations with liver-related conditions, and 51.3% (95%CI: 46.9-55.6%) among people who inject drugs. Genotypes 1 (52.6%) and 3 (38.0%) were most frequent. Evidence was found for statistically-significant differences in prevalence by country, but not for a temporal decline in prevalence. CA is one of the most affected regions by HCV infection with Uzbekistan enduring one of the highest prevalence levels worldwide. Ongoing HCV transmission seems to be driven by injecting drug use and healthcare exposures.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Population classification into categories by risk of exposures to hepatitis C virus (HCV) infection.
Figure 2
Figure 2
Flow chart of the process by which articles were selected for inclusion in this systematic review of hepatitis C virus (HCV) incidence and prevalence in Central Asia, adapted from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 guidelines.
See this image and copyright information in PMC

References

    1. WHO. Global Hepatitis Report, 2017. Online at: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (2017).
    1. Brown RS, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver transplantation. 2003;9(11):S10–S3. doi: 10.1053/jlts.2003.50244. - DOI - PubMed
    1. Ayoub H, Abu‐Raddad LJ. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. Journal of viral hepatitis. 2017;24(6):486–95. doi: 10.1111/jvh.12671. - DOI - PubMed
    1. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Online at: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (2016).
    1. World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Online at: http://apps.who.int/iris/handle/10665/206453 (2016).

Publication types